Israel360

RCK
DryGair
Deloitte
Nrgene
CannDoc
BioDiligence
CannaSoul
Eybna
Stero/CannaMore/CannaDu
Hebrew University
Invest in Israel
InnoCann
iCANsee
Seach
Lumir
Izun
Kanabo
Cannabics
Intelicanna
Panaxia
I am a tooltip for a hotspot
CiiTech
Cannassure
RCK
DryGair
Deloitte
CannDoc
BioDiligence
CannaSoul
Eybna
Stero/CannaMore/CannaDu
Hebrew University
Invest in Israel
InnoCann
Lumir
iCANsee
Nrgene
Izun
Seach
Kanabo
Cannabics Pharma
Intelicanna
Panaxia
I am a tooltip for a hotspot
CiiTech
Cannassure

Click on the interactive map to find out more about presenting companies

$99 ACCESS

Watch Replay

powered by Crowdcast

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S public company that is developing a platform that leverages novel drug-screening tools to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.

Contact Us

Introduction to Cannabics Pharmaceuticals Inc. Lab

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S public company that is developing a platform that leverages novel drug-screening tools to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.

Contact Us

Introduction to Cannabics Pharmaceuticals Inc. Lab

Invest in Israel, the Israeli Investment Promotion Agency (IPA), is an integrative body within the Ministry of Economy and Industry that serves as a one-stop shop for a wide range of potential and existing investors. Invest in Israel identify lucrative investment opportunities, map potential obstacles and help fast-track investment. Our advantage lies in our ability to bridge between private client needs and to promote activities within the framework of the government.

Contact Us

Videos

Israel is a leading site of investment far beyond what its small size and short history might suggest. With a leading economy, a striking concentration of innovative people and countless cutting edge technologies, Israel is the best place for your company to grow.​

Docs

Israel's Medical Cannabis Innovation

Invest in Israel, the Israeli Investment Promotion Agency (IPA), is an integrative body within the Ministry of Economy and Industry that serves as a one-stop shop for a wide range of potential and existing investors. Invest in Israel identify lucrative investment opportunities, map potential obstacles and help fast-track investment. Our advantage lies in our ability to bridge between private client needs and to promote activities within the framework of the government.

Contact Us

Videos

Israel is a leading site of investment far beyond what its small size and short history might suggest. With a leading economy, a striking concentration of innovative people and countless cutting edge technologies, Israel is the best place for your company to grow.​

Docs

Israel's Medical Cannabis Innovation

Innocan Pharma™ is a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations.

Innocan Pharma is led by a multi-disciplinary management and R&D team, headed by: 

Iris Bincovich, an experienced healthcare Executive, Ron Mayron, former CEO of Teva Israel, one of the largest generic pharmaceutical companies in the world. Yoram Drucker Founder of two Nasdaq traded companies – Pluristem & Brainstorm, working with stem cells, Nir Avram, former member of the pharma innovation team at Perrigo, Prof. Hezy Barenholz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University – Jerusalem and Prof. Daniel Offen, a leading researcher specializing in Neuroscience and Exosome technology, Head of the Department of Human Molecular Genetics and Biochemistry at Tel Aviv University.

Contact Us

Videos

Innocan Pharma Introduction Video

Innocan Pharma plans to collaborate with Tel Aviv University to find treatment for COVID-19

Innocan Pharma is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”) with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. The Company’s operations and research and development activities are based in Israel.

Innocan Pharma’s business can be described as three distinct operating segments relating to the incorporation in products of CBD in their formulation: (i) the research and development of the treatment of Covid-19 (and other viruses causing lung inflammation as well as other central nervous system (CNS) diseases such as epilepsy and Alzheimer’s Disease) by using CBD loaded exosomes (“CLX”); (ii) the research and development of the use of CBD loaded liposomes to provide pain relief and treat epilepsy and other central nervous system disorders and other indications; and (iii) the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain.

Innocan Pharma™ is a specialty pharmaceutical company, developing products that harness the unique properties of Cannabinoids combined with smart delivery formulations.

Innocan Pharma is led by a multi-disciplinary management and R&D team, headed by: 

Iris Bincovich, an experienced healthcare Executive, Ron Mayron, former CEO of Teva Israel, one of the largest generic pharmaceutical companies in the world. Yoram Drucker Founder of two Nasdaq traded companies – Pluristem & Brainstorm, working with stem cells, Nir Avram, former member of the pharma innovation team at Perrigo, Prof. Hezy Barenholz, Head of the Laboratory of Membrane and Liposome Research of the Hebrew University – Jerusalem and Prof. Daniel Offen, a leading researcher specializing in Neuroscience and Exosome technology, Head of the Department of Human Molecular Genetics and Biochemistry at Tel Aviv University.

Contact Us

Videos

Innocan Pharma Introduction Video

Innocan Pharma plans to collaborate with Tel Aviv University to find treatment for COVID-19

Innocan Pharma is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol (“CBD”) with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. The Company’s operations and research and development activities are based in Israel.

Innocan Pharma’s business can be described as three distinct operating segments relating to the incorporation in products of CBD in their formulation: (i) the research and development of the treatment of Covid-19 (and other viruses causing lung inflammation as well as other central nervous system (CNS) diseases such as epilepsy and Alzheimer’s Disease) by using CBD loaded exosomes (“CLX”); (ii) the research and development of the use of CBD loaded liposomes to provide pain relief and treat epilepsy and other central nervous system disorders and other indications; and (iii) the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products for relief of psoriasis symptoms as well as the treatment of muscle pain and rheumatic pain.

Evidence-Based Cannabis Solutions.
 
Lumir Lab is a research and development platform – addressing the lack of scientific validity in the cannabis field, through a unique multidisciplinary approach led by a world-leading cannabis-oriented scientific team.
 
Offering Design, Management & Execution of a wide array of R&D activities including:
– Analytical Chemistry & Cannabis Testing
– Pre-clinical & Clinical Studies
– Formulation & Product Development
– Safety, Pharmacology & Toxicology studies
 
Lumir Lab is located in Jerusalem Biotechnology Park, Hadassah Ein-Kerem – Hebrew University Campus.

Contact Us

Videos

The story of Lumír Hanuš, one of the first and best cannabis researchers in the world.

Docs

Lumir Lab Israel

Evidence-Based Cannabis Solutions.
 
Lumir Lab is a research and development platform – addressing the lack of scientific validity in the cannabis field, through a unique multidisciplinary approach led by a world-leading cannabis-oriented scientific team.
 
Offering Design, Management & Execution of a wide array of R&D activities including:
– Analytical Chemistry & Cannabis Testing
– Pre-clinical & Clinical Studies
– Formulation & Product Development
– Safety, Pharmacology & Toxicology studies
 
Lumir Lab is located in Jerusalem Biotechnology Park, Hadassah Ein-Kerem – Hebrew University Campus.

Contact Us

Videos

The story of Lumír Hanuš, one of the first and best cannabis researchers in the world.

Docs

Lumir Lab Israel

CannRx is a subsidiary of Izun Phramaceuticals, a leading company in the boutique pharmaceutical area of Botanical Medicine. Izun has developed extensive technology to analyze plant material and understand the bioactivity of the various compounds found within the plant. Utilizing this technology, Izun can boast of a successful track record in developing breakthrough products in the areas of oral health, oncology support, wound care and women’s health.  Izun utilizes the poly-molecular characteristic present in all plants to develop products that are more efficacious than typical single molecule pharmaceutical products. The Izun concept is that all our natural plant products should be “as effective as a drug and as safe as a natural product”.

Videos

Saul interviews Dr Billy Levine (Founder IZUN)

Learn about the VCT extractor system

CannRx’s mission is to develop scientifically-based proprietary cannabis technologies and reliable, repeatable, and efficacy driven products using research and leveraging our staff’s scientific expertise.

Maximizing the benefits that cannabis provides requires sophisticated knowledge to:

  • identify the correct composition and ratio of plant’s active molecules,
  • maximize  the extraction process that will optimize these compounds and
  • formulate them into a delivery system with precision dosing.

It is important to understand that the required (or desired) active compounds vary with the specific indication. The active compounds in a cannabis sleep product will be different from those in an epilepsy product, and both will be different from those in a pain product. That is why CannRx considers and analyzes a wide range of cannabinoids, terpenes and other bioactive compounds in its cannabis strains and blends, analyzing and learning the interactions between these compounds.

Canndoc has been pioneering Pharma-Grade cannabis for more than 12 years. Over the years, Canndoc provided more than 750,000 doses to 20,000 patients, establishing its position as a venerable player in this global industry, demonstrating significant expertise across the entire value chain from research, cultivation, and processing, to product development and advanced GMP clinical trials pipeline initiation.

Driven by the mission of meeting patients’ needs and improving their quality of life, Canndoc holds product efficacy to be of paramount importance, delivering Good Manufacturing Practice (GMP) pharma-grade cannabis solutions to achieve better patient health and treatment outcomes.

Contact Us

Videos

CANNDOC imported the first ever commercial shipment of medical cannabis to Israel

Ehud Barak Cannatech Davos

Canndoc has been pioneering Pharma-Grade cannabis for more than 12 years. Over the years, Canndoc provided more than 750,000 doses to 20,000 patients, establishing its position as a venerable player in this global industry, demonstrating significant expertise across the entire value chain from research, cultivation, and processing, to product development and advanced GMP clinical trials pipeline initiation.

Driven by the mission of meeting patients’ needs and improving their quality of life, Canndoc holds product efficacy to be of paramount importance, delivering Good Manufacturing Practice (GMP) pharma-grade cannabis solutions to achieve better patient health and treatment outcomes.

Contact Us

Videos

CANNDOC imported the first ever commercial shipment of medical cannabis to Israel

Ehud Barak Cannatech Davos

CiiTECH is a leading consumer brand company focusing on discovering and commercialising cannabis health products. Our flagship brand ‘Provacan’ is a leading CBD brand in the UK. Today we are developing patent-pending formulations together with the Hebrew University for both weight loss and hangovers. We are seeking strategic partners and growth capital for expansion into new markets and channels.

Contact Us

Videos

How to Build A CBD Brand

CiiTECH was a proud Bronze Sponsor of the Hemp & CBD Expo in Birmingham, UK. Together with CiiTECH brands Provacan, The HuGG Co and IMPACT, it was a great event.

CiiTECH is a leading consumer brand company focusing on discovering and commercialising cannabis health products. Our flagship brand ‘Provacan’ is a leading CBD brand in the UK. Today we are developing patent-pending formulations together with the Hebrew University for both weight loss and hangovers. We are seeking strategic partners and growth capital for expansion into new markets and channels.

Contact Us

Videos

How to Build A CBD Brand

CiiTECH was a proud Bronze Sponsor of the Hemp & CBD Expo in Birmingham, UK. Together with CiiTECH brands Provacan, The HuGG Co and IMPACT, it was a great event.

Deloitte Israel is one of Israel’s leading professional services firms, providing a wide range of world-class audit, tax, consulting, financial advisory and trust services. Through 100 partners and directors and over 1000 employees, Deloitte Israel serve domestic and international clients, public institutions and promising fast-growing companies whose shares are traded on the Israeli, US and European capital markets.

Our multidisciplinary, collaborative approach to client service, combined with an ability to look at business issues from every angle, is what sets us apart. Whether you are one of Israel’s largest companies, or a small business with ambition to grow, we can bring you a 360° view of your business challenges. We believe this is our difference.

Contact Us

Why Cannabis in Israel

Videos

Deloitte Israel - A client's journey

Nadav Gil

Partner | National Leader
Global Investment and Innovation Incentives Cannabis Leader
Deloitte Israel
Ngil@Deloitte.co.il

Nadav Gil is the Head of the Cannabis practice, as well as the Global Investment and Innovation Incentives practice at Deloitte Israel. He has extensive experience accompanying companies through their business development stages in all sectors, including the Investment Encouragement Law of 1959 and its implementation, and raising funds for research and development from other government funding sources in Israel and abroad. Nadav represents companies during their interaction with local tax authorities, the Innovation Authority, and Investment Center in the Ministry of Economy and the European Commission. Over the years, Nadav has accompanied start-up companies, multinational firms, traditional industry enterprises and many public companies. Nadav is a member of the global Gi3 leadership and the head of the Cannabis-tech field in Israel. Nadav is Leading the Israeli Canna-Tech Industry in Deloitte.

Deloitte Israel is one of Israel’s leading professional services firms, providing a wide range of world-class audit, tax, consulting, financial advisory and trust services. Through 100 partners and directors and over 1000 employees, Deloitte Israel serve domestic and international clients, public institutions and promising fast-growing companies whose shares are traded on the Israeli, US and European capital markets.

Our multidisciplinary, collaborative approach to client service, combined with an ability to look at business issues from every angle, is what sets us apart. Whether you are one of Israel’s largest companies, or a small business with ambition to grow, we can bring you a 360° view of your business challenges. We believe this is our difference.

Contact Us

Why Cannabis in Israel

Videos

Deloitte Israel - A client's journey

Nadav Gil

Partner | National Leader
Global Investment and Innovation Incentives Cannabis Leader
Deloitte Israel
Ngil@Deloitte.co.il

Nadav Gil is the Head of the Cannabis practice, as well as the Global Investment and Innovation Incentives practice at Deloitte Israel. He has extensive experience accompanying companies through their business development stages in all sectors, including the Investment Encouragement Law of 1959 and its implementation, and raising funds for research and development from other government funding sources in Israel and abroad. Nadav represents companies during their interaction with local tax authorities, the Innovation Authority, and Investment Center in the Ministry of Economy and the European Commission. Over the years, Nadav has accompanied start-up companies, multinational firms, traditional industry enterprises and many public companies. Nadav is a member of the global Gi3 leadership and the head of the Cannabis-tech field in Israel. Nadav is Leading the Israeli Canna-Tech Industry in Deloitte.

Novel and improved Cannabidiol (CBD)-based treatment solutions, to reduce the side effects and need for steroid therapy.

An IP-based pre-clinical and clinical stage research platform company committed to the development of novel and improved cannabis-based treatments with a groundbreaking partnership with the largest HMO in Israel with multiple simultaneous projects, clinical trials in the pipeline for 2020-2021.

CannaDu is an exclusive Biotech Venture Capital Fund,  focused on Cannabis investments in fields of pharmaceuticals, wellness, medical applications & devices.

Contact Us

Stero

STERO Biotechs Ltd., founded in 2017 and headquartered in Israel, is a clinical R&D company committed to solve the unmet need of:
1) Enhancing the therapeutic effect of steroid treatments.
2) Lowering the dosage needed in steroid treatments, thus lowering the treatment’s horrific side effects.
3) Allowing refractory patients to begin responding to the steroid treatments they need.
All by using Stero’s CBD-based treatment.

Stero currently has ongoing phase IIa clinical trials in Crohn’s disease, Urticaria and in 1-2 additional indications within 2020-2021. Stero plans to reach FDA pre IND meeting and guidelines to initiate its first phase IIb clinical trial within 2022.

The partnership with MOR allows deep support to Stero’s clinical trials. Mor’s unique assistance creates tailor-made connections to best available hospitals, KOLs, advisors, and physicians most suited at lower costs and high efficiency – per research.

Stero’s patent was filed on May 2016, Issued in the US on August 2018!! And at national phase within Canada, Europe and more.

CannaMore

An IP-based pre-clinical and clinical stage research platform company committed to the development of novel and improved cannabis-based treatments with a groundbreaking partnership with the largest HMO in Israel with multiple simultaneous projects, clinical trials in the pipeline for 2020-2021.

CannaDu

Exclusive Biotech Venture Capital

CannaDu is an exclusive Biotech Venture Capital Fund,  focused on Cannabis investments in fields of pharmaceuticals, wellness, medical applications & devices

Cannabis Innovation Center

Stero Biotechs Ltd

Novel and improved Cannabidiol (CBD)-based treatment solutions, to reduce the side effects and need for steroid therapy.

An IP-based pre-clinical and clinical stage research platform company committed to the development of novel and improved cannabis-based treatments with a groundbreaking partnership with the largest HMO in Israel with multiple simultaneous projects, clinical trials in the pipeline for 2020-2021.

CannaDu is an exclusive Biotech Venture Capital Fund,  focused on Cannabis investments in fields of pharmaceuticals, wellness, medical applications & devices.

Contact Us

Stero

STERO Biotechs Ltd., founded in 2017 and headquartered in Israel, is a clinical R&D company committed to solve the unmet need of:
1) Enhancing the therapeutic effect of steroid treatments.
2) Lowering the dosage needed in steroid treatments, thus lowering the treatment’s horrific side effects.
3) Allowing refractory patients to begin responding to the steroid treatments they need.
All by using Stero’s CBD-based treatment.

Stero currently has ongoing phase IIa clinical trials in Crohn’s disease, Urticaria and in 1-2 additional indications within 2020-2021. Stero plans to reach FDA pre IND meeting and guidelines to initiate its first phase IIb clinical trial within 2022.

The partnership with MOR allows deep support to Stero’s clinical trials. Mor’s unique assistance creates tailor-made connections to best available hospitals, KOLs, advisors, and physicians most suited at lower costs and high efficiency – per research.

Stero’s patent was filed on May 2016, Issued in the US on August 2018!! And at national phase within Canada, Europe and more.

CannaMore

An IP-based pre-clinical and clinical stage research platform company committed to the development of novel and improved cannabis-based treatments with a groundbreaking partnership with the largest HMO in Israel with multiple simultaneous projects, clinical trials in the pipeline for 2020-2021.

CannaDu

Exclusive Biotech Venture Capital

CannaDu is an exclusive Biotech Venture Capital Fund,  focused on Cannabis investments in fields of pharmaceuticals, wellness, medical applications & devices

Cannabis Innovation Center

Stero Biotechs Ltd

Located within the hotbed of Israeli technological innovation, Intelicanna has positioned itself as a world leader in medical cannabis innovations.

Intelicanna is a publicly traded, international medical cannabis company based in Israel.

​From plant genetics and agro technologies to downstream processing and product development, Intelicanna will leverage the wide spectrum of proven Israeli know-how to revolutionize the process of medical cannabis cultivation and processing.

Contact Us

Capitalizing on our specialists’ vast experience and deep understanding of the medical cannabis market, Intelicanna’s ‘R&D to commercialization’ strategy aims to create a global portfolio of high quality products and technologies that will help optimize the process of cultivating and processing cannabis within the industry.

In Israel, Intelicanna will cultivate consistent, high quality medical cannabis for the local market in a state of the art, snow-white medifarm facility that will incorporate various agro and automation technologies that enhance the quality of our cannabis.  

​Intelicanna is also developing a medical cannabis-based cream for treating the symptoms of Psoriasis and other skin irritations.

Internationally, Intelicanna continues to evaluate opportunities that would allow it to increase its international footprint.

Intelicanna also seeks partnerships with companies both in Israel and worldwide to co-develop innovative cannabis products and solutions.

Located within the hotbed of Israeli technological innovation, Intelicanna has positioned itself as a world leader in medical cannabis innovations.

Intelicanna is a publicly traded, international medical cannabis company based in Israel.

​From plant genetics and agro technologies to downstream processing and product development, Intelicanna will leverage the wide spectrum of proven Israeli know-how to revolutionize the process of medical cannabis cultivation and processing.

Contact Us

Capitalizing on our specialists’ vast experience and deep understanding of the medical cannabis market, Intelicanna’s ‘R&D to commercialization’ strategy aims to create a global portfolio of high quality products and technologies that will help optimize the process of cultivating and processing cannabis within the industry.

In Israel, Intelicanna will cultivate consistent, high quality medical cannabis for the local market in a state of the art, snow-white medifarm facility that will incorporate various agro and automation technologies that enhance the quality of our cannabis.  

​Intelicanna is also developing a medical cannabis-based cream for treating the symptoms of Psoriasis and other skin irritations.

Internationally, Intelicanna continues to evaluate opportunities that would allow it to increase its international footprint.

Intelicanna also seeks partnerships with companies both in Israel and worldwide to co-develop innovative cannabis products and solutions.

Cannassure (TASE symbol: CSURE) has established a holistic & integrated value chain operation for medical cannabis products. Activity includes breeding & cultivation in an indoor growing facility growing aeroponically, processing, packaging & Supply chain management alongside with R&D activities. This enables Cannassure to produce and develop a wide range of effective, high standard and affordable medical cannabis products. The company is a spin-off of Solbar Food Technologies, a 60-year leading manufacturer of food products in Israel, providing Cannassure with decades of knowledge and experience in botanical extraction and manufacturing. Cannassure is committed to quality, integrity and innovation.

Contact Us

Docs

Power Point Presentation

Corporate Deck

Cannassure (TASE symbol: CSURE) has established a holistic & integrated value chain operation for medical cannabis products. Activity includes breeding & cultivation in an indoor growing facility growing aeroponically, processing, packaging & Supply chain management alongside with R&D activities. This enables Cannassure to produce and develop a wide range of effective, high standard and affordable medical cannabis products. The company is a spin-off of Solbar Food Technologies, a 60-year leading manufacturer of food products in Israel, providing Cannassure with decades of knowledge and experience in botanical extraction and manufacturing. Cannassure is committed to quality, integrity and innovation.

Contact Us

Docs

Power Point Presentation

Corporate Deck

CannaSoul Analytics is a global leader in cannabis research and development. Dedicated to developing scientific intellectual property, medical product and technologies. CannaSoul is backed by our robust scientific analysis.

Founded by world-renowned cannabis researcher Prof. Dedi Meiri from the Technion – Israel Institute of Technology, CannaSoul utilizes proprietary analytical expertise based on our accumulated clinical data and Prof. Meiri’s pioneering research. Adhering to the principles and spirit of GCLP, the company is accredited under ISO 17025 and operates under the supervision of the Israel Health Ministry’s Cannabis Unit.

Contact Us

Videos

Dr. Dedi Meiri: Israeli researcher and head of Laboratory of Cancer Biology and Cannabinoid Research

Dr. David "Dedi" Meiri from the Cancer Research lab at the Technion in Israel (aka "Dedi's Lab") takes us through a fascinating presentation on the identification of the effects of different Cannabis extracts on the proliferation and cell death of various cancer cell lines (and classification) according to genetic profile.

CannaSoul Analytics is a global leader in cannabis research and development. Dedicated to developing scientific intellectual property, medical product and technologies. CannaSoul is backed by our robust scientific analysis.

Founded by world-renowned cannabis researcher Prof. Dedi Meiri from the Technion – Israel Institute of Technology, CannaSoul utilizes proprietary analytical expertise based on our accumulated clinical data and Prof. Meiri’s pioneering research. Adhering to the principles and spirit of GCLP, the company is accredited under ISO 17025 and operates under the supervision of the Israel Health Ministry’s Cannabis Unit.

Contact Us

Videos

Dr. Dedi Meiri: Israeli researcher and head of Laboratory of Cancer Biology and Cannabinoid Research

Dr. David "Dedi" Meiri from the Cancer Research lab at the Technion in Israel (aka "Dedi's Lab") takes us through a fascinating presentation on the identification of the effects of different Cannabis extracts on the proliferation and cell death of various cancer cell lines (and classification) according to genetic profile.

Eybna is a technology company and a leading terpene manufacturer. Eybna’s forward-thinking R&D center aims to contribute to the health of mankind by utilizing the therapeutic benefits of cannabis phytochemicals, with a focus on terpenes. Eybna’s strong and profound partnership with academia and leading industry partners, allows the company to constantly integrate advanced research in the process of product development, transforming valuable scientific knowledge into easily applicable products, for the immediate benefit of people worldwide. Eybna has an R&D center based in Israel and a US office based in California.

Contact Us

Videos

eybna technologies: "The essence of cannabis: A terpene workshop in 5d"

Nadav eyal - eybna technologies on bio control program in cannabis

Docs

The Cannabis Terpiodic Table

Eybna is a technology company and a leading terpene manufacturer. Eybna’s forward-thinking R&D center aims to contribute to the health of mankind by utilizing the therapeutic benefits of cannabis phytochemicals, with a focus on terpenes. Eybna’s strong and profound partnership with academia and leading industry partners, allows the company to constantly integrate advanced research in the process of product development, transforming valuable scientific knowledge into easily applicable products, for the immediate benefit of people worldwide. Eybna has an R&D center based in Israel and a US office based in California.

Contact Us

Videos

eybna technologies: "The essence of cannabis: A terpene workshop in 5d"

Nadav eyal - eybna technologies on bio control program in cannabis

Docs

The Cannabis Terpiodic Table

Our Mission
Bring consistency, high-quality and standardization to make medical cannabis accessible for those who need it. 
Panaxia is modernizing the medical field with revolutionary pharmaceutical solutions that utilize the unique properties and benefits of medical cannabis. As a leader in this rapidly developing medical arena, Panaxia is spearheading the adoption of cannabis-based treatments through a variety of familiar delivery methods that can radically improve the lives of those with a wide range of medical conditions.

Our Story
Decades of experience to lead the way forward.
Leveraging over four decades of experience in the pharmaceutical industry, Panaxia is part of a leading group of Israeli pharmaceutical companies. Thanks to our relentless emphasis on research and development, today our entire group of companies offers more than 600 medical products in over 30 international markets to treat a wide range of symptoms and conditions.

Our Quest
Research. Develop. Repeat.
As pharmaceutical research on cannabis continues to evolve, we intend to stay at the forefront of the field. With over 20 percent of our workforce dedicated to research and development, we are committed to continuously increasing our knowledge and understanding of this plant’s wide range of therapeutic benefits. Our goal is to increase accessibility to pharmaceutical cannabis with cutting-edge products and a variety of new and familiar delivery methods.
 

Contact Us

Videos

Learn from DaDI sEGAL fOUNDER AND ceo OF pANAXIA

Duke Rodreguez - Ultra Health (Panaxia Partner)

Our Mission
Bring consistency, high-quality and standardization to make medical cannabis accessible for those who need it. 
Panaxia is modernizing the medical field with revolutionary pharmaceutical solutions that utilize the unique properties and benefits of medical cannabis. As a leader in this rapidly developing medical arena, Panaxia is spearheading the adoption of cannabis-based treatments through a variety of familiar delivery methods that can radically improve the lives of those with a wide range of medical conditions.

Our Story
Decades of experience to lead the way forward.
Leveraging over four decades of experience in the pharmaceutical industry, Panaxia is part of a leading group of Israeli pharmaceutical companies. Thanks to our relentless emphasis on research and development, today our entire group of companies offers more than 600 medical products in over 30 international markets to treat a wide range of symptoms and conditions.

Our Quest
Research. Develop. Repeat.
As pharmaceutical research on cannabis continues to evolve, we intend to stay at the forefront of the field. With over 20 percent of our workforce dedicated to research and development, we are committed to continuously increasing our knowledge and understanding of this plant’s wide range of therapeutic benefits. Our goal is to increase accessibility to pharmaceutical cannabis with cutting-edge products and a variety of new and familiar delivery methods.
 

Contact Us

Videos

Learn from DaDI sEGAL fOUNDER AND ceo OF pANAXIA

Duke Rodreguez - Ultra Health (Panaxia Partner)

Kanabo is creating a new standard in the medical cannabis industry by building a holistic ecosystem that works together in synergy to improve the well-being of millions around the world. With a focus on the distribution of Cannabis-derived products for medical patients, and non-THC products for CBD consumers, Kanabo has conducted extensive R&D in order to develop high-quality Cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions – making use easy and accessible for anyone in need of treatment. 

The formulas have been designed specifically for use with the VapePod®, Kanabo’s cutting-edge cannabis oil vaporization device, that includes metered-dosing, allowing extremely accurate consumption. The VapePod is the first-ever medically certified vaporization delivery system for cannabis oils. Each product goes through rigorous third-party testing, including safety and efficiency/efficacy tests conducted in Israel. The device is registered as a CE Medical Device in the European Union. 

Kanabo has been busy the last year with R&D activities that include several milestones achieved: licenses for Cannabis research in Israel, and pre-clinical trials for insomnia and sleep disorders. We are committed to ongoing stability and safety tests for the CBD and THC product lines to engender trust from our consumers. In the lab, we’re working on a variety of new applications for medical cannabis. Kanabo is on the cusp of creating a new IP that will offer other delivery methods for patients with high bioavailability and fast onset, bypassing the First-pass effect.

Contact Us

Videos

How to Turn a Cannabis Product into a Medical Drug: Kanabo Research

The global markets rush to legalise cannabis has led to a surge in green companies lighting up stock markets worldwide. Avihu Tamir, the CEO of medical cannabis company, Kanabo Research, discusses the current output of the Israeli company.

VapePod is disrupting the medical cannabis market with a quality, medically certified delivery system that works synergistically with patented, precision-targeted formulas. This comprehensive offering is designed to provide trusted relief to those suffering from a variety of disorders.

The VapePod vaporizer is produced in a certified GMP medical facility in full compliance with ISO13485, setting a new medical standard, engendering trust and ensuring peace of mind for our global clientele. The device was approved in 2018 as a medical device for cannabis extracts by the Israeli Ministry of Health, and is the first-ever medically certified vaporizer for the delivery of cannabis based formulas.

The company is currently selling initial products in the UK and Germany, and is ready to scale up to meet market demands and projected sales and revenues. With a newly acquired CE mark registered in Germany, Kanabo is already in talks with several distributors who have taken an interest in partnering in the EU. The horizon holds future products in development with the second version of VapePod Medical, licensed medical cannabis oils, and Clinical trials. 

Our goal is to lead the emerging markets of medical cannabis in a category of medical vaporization, providing a healthy alternative for many of the patients that are smoking cannabis today. Committed to our standard, having a certified medical device and an EU-GMP production, we’ve built great partnerships and continue to look for additional distributors. 

Kanabo is creating a new standard in the medical cannabis industry by building a holistic ecosystem that works together in synergy to improve the well-being of millions around the world. With a focus on the distribution of Cannabis-derived products for medical patients, and non-THC products for CBD consumers, Kanabo has conducted extensive R&D in order to develop high-quality Cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions – making use easy and accessible for anyone in need of treatment. 

The formulas have been designed specifically for use with the VapePod®, Kanabo’s cutting-edge cannabis oil vaporization device, that includes metered-dosing, allowing extremely accurate consumption. The VapePod is the first-ever medically certified vaporization delivery system for cannabis oils. Each product goes through rigorous third-party testing, including safety and efficiency/efficacy tests conducted in Israel. The device is registered as a CE Medical Device in the European Union. 

Kanabo has been busy the last year with R&D activities that include several milestones achieved: licenses for Cannabis research in Israel, and pre-clinical trials for insomnia and sleep disorders. We are committed to ongoing stability and safety tests for the CBD and THC product lines to engender trust from our consumers. In the lab, we’re working on a variety of new applications for medical cannabis. Kanabo is on the cusp of creating a new IP that will offer other delivery methods for patients with high bioavailability and fast onset, bypassing the First-pass effect.

Contact Us

Videos

How to Turn a Cannabis Product into a Medical Drug: Kanabo Research

The global markets rush to legalise cannabis has led to a surge in green companies lighting up stock markets worldwide. Avihu Tamir, the CEO of medical cannabis company, Kanabo Research, discusses the current output of the Israeli company.

VapePod is disrupting the medical cannabis market with a quality, medically certified delivery system that works synergistically with patented, precision-targeted formulas. This comprehensive offering is designed to provide trusted relief to those suffering from a variety of disorders.

The VapePod vaporizer is produced in a certified GMP medical facility in full compliance with ISO13485, setting a new medical standard, engendering trust and ensuring peace of mind for our global clientele. The device was approved in 2018 as a medical device for cannabis extracts by the Israeli Ministry of Health, and is the first-ever medically certified vaporizer for the delivery of cannabis based formulas.

The company is currently selling initial products in the UK and Germany, and is ready to scale up to meet market demands and projected sales and revenues. With a newly acquired CE mark registered in Germany, Kanabo is already in talks with several distributors who have taken an interest in partnering in the EU. The horizon holds future products in development with the second version of VapePod Medical, licensed medical cannabis oils, and Clinical trials. 

Our goal is to lead the emerging markets of medical cannabis in a category of medical vaporization, providing a healthy alternative for many of the patients that are smoking cannabis today. Committed to our standard, having a certified medical device and an EU-GMP production, we’ve built great partnerships and continue to look for additional distributors. 

Izun technology unlocks the natural benefits of botanicals to provide more effective and safer solutions for a range of medical needs.

Izun Pharmaceuticals Corporation is dedicated to harnessing the power of nature’s botanical ingredients to create innovative products.

Izun is focused on improving the quality of life for various indications, such as cancer patients through a range of oncology support products.

Contact Us

Videos

Saul interviews IZUN FOunder Dr. Billy Levine

Learn about the VCT extractor system

Izun technology unlocks the natural benefits of botanicals to provide more effective and safer solutions for a range of medical needs.

Izun Pharmaceuticals Corporation is dedicated to harnessing the power of nature’s botanical ingredients to create innovative products.

Izun is focused on improving the quality of life for various indications, such as cancer patients through a range of oncology support products.

Contact Us

Videos

Saul interviews IZUN FOunder Dr. Billy Levine

Learn about the VCT extractor system

RCK is an Israeli cannabis company, breeding tailor-made cannabis strains, and stable hybrid-seeds. Being the first company to operate a methodological marker-assisted-breeding of cannabis, having cutting-edge proprietary technologies and led by a professional team, we open the gate to a new era of cannabis genetics. The Chain Begins With Us!

Contact Us

Docs

Challenges in Cannabis Breeding

Stable elite hybrid-seeds

Seeds are superior to clones in many aspects: stronger roots, higher yield, reduced inputs and more. However, cannabis growers still prefer clones, since seeds lack the needed uniformity. We use our unique breeding technology to stabilize strains and develop elite hybrid-seeds. All seeds of a certain strain will carry exactly the same genetic charge, enabling industrial-scale cannabis agriculture – similar to other mass-production crops. Just sow and grow!

Cannabinoid profiles

Cannabinoids are the main contributors to the effect of cannabis. To date, over 100 different cannabinoids are known, of which a few dozen are bio-synthesized in the cannabis plant. We develop strains with precise cannabinoid-profiles, following the “entourage effect” principle and optimizing the medical effect of each strain. Our unique strains include high percentage of rare cannabinoids, in addition to the major two – THC and CBD.

Breeding technology

During the past 80 years, scientists and breeders have been developing advanced tools and methodologies for enhancing the breeding process. Utilizing our vast experience in breeding mass-production crops, we developed advanced cannabis-specific breeding technology. Our proprietary toolbox include various cannabis-specific biomarkers, unique technology for accurate self-pollination and professional methodology. Using our technology, we are able to increase accuracy in the breeding process while shortening it by half.

Exploring new applications

THC and CBD are the most studied cannabinoids and are the key components of cannabis. However, minor less-studied cannabinoids, such as CBC or CBG contribute to the holistic effect of cannabis and their medical properties have yet to be discovered. We study the medical effect of full-spectrum extracts, as well as isolated cannabinoids, in cooperation with leading Israeli research institutes. The research results enable us to develop new cannabis products for as yet unknown applications.

RCK is an Israeli cannabis company, breeding tailor-made cannabis strains, and stable hybrid-seeds. Being the first company to operate a methodological marker-assisted-breeding of cannabis, having cutting-edge proprietary technologies and led by a professional team, we open the gate to a new era of cannabis genetics. The Chain Begins With Us!

Contact Us

Docs

Challenges in Cannabis Breeding

Stable elite hybrid-seeds

Seeds are superior to clones in many aspects: stronger roots, higher yield, reduced inputs and more. However, cannabis growers still prefer clones, since seeds lack the needed uniformity. We use our unique breeding technology to stabilize strains and develop elite hybrid-seeds. All seeds of a certain strain will carry exactly the same genetic charge, enabling industrial-scale cannabis agriculture – similar to other mass-production crops. Just sow and grow!

Cannabinoid profiles

Cannabinoids are the main contributors to the effect of cannabis. To date, over 100 different cannabinoids are known, of which a few dozen are bio-synthesized in the cannabis plant. We develop strains with precise cannabinoid-profiles, following the “entourage effect” principle and optimizing the medical effect of each strain. Our unique strains include high percentage of rare cannabinoids, in addition to the major two – THC and CBD.

Breeding technology

During the past 80 years, scientists and breeders have been developing advanced tools and methodologies for enhancing the breeding process. Utilizing our vast experience in breeding mass-production crops, we developed advanced cannabis-specific breeding technology. Our proprietary toolbox include various cannabis-specific biomarkers, unique technology for accurate self-pollination and professional methodology. Using our technology, we are able to increase accuracy in the breeding process while shortening it by half.

Exploring new applications

THC and CBD are the most studied cannabinoids and are the key components of cannabis. However, minor less-studied cannabinoids, such as CBC or CBG contribute to the holistic effect of cannabis and their medical properties have yet to be discovered. We study the medical effect of full-spectrum extracts, as well as isolated cannabinoids, in cooperation with leading Israeli research institutes. The research results enable us to develop new cannabis products for as yet unknown applications.

The Hebrew University School of Pharmacy’s Multidisciplinary Center for Cannabinoid Research is integrating, coordinating and conducting this exciting research on cannabinoids, endocannabinoids and medical Cannabis, focusing on the following areas:

  • CANCER
  • PAIN
  • INFLAMATION & STRESS MANAGEMENT
  • IMMUNITY
  • METABOLISM
  • DRUG DELIVERY & NANOTECHNOLOGY
  • PHARMACEUTICAL CHEMISTRY
  • NEUROSCIENCE and PLANT SCIENCE & GENETICS


One of its major objectives is to foster collaborations between its own participating laboratories and many other well-established groups around the globe who are conducting research on cannabinoids, endocannabinoids and medical Cannabis.

Contact Us

Videos

Scientists from the Hebrew University (HU) have pioneered medical marijuana research for over 50 years.

The establishment of the Multidisciplinary Center for Cannabinoid Research (MCCR) at the School of Pharmacy of the Hebrew University in Israel has great relevance at this specific time in modern history – a time when both international academic institutions and mega-pharmaceutical companies all around the globe are channeling enormous efforts towards, and investing heavily in basic and clinical research in this exciting new field. 

The MCCR fills the need for a central, professional body who undertakes to integrate and coordinate all these worldwide research activities into one cohesive whole – assisting collaborations and disseminating collective information.  

The MCCR is staffed by eminent scientists and Medical Doctors from a variety of faculties at the Hebrew University and Hadassah-University Medical Center. The faculties involved span the entire spectrum relevant to this research – from Medicine, Medicinal Chemistry, Biotechnology, Biopolymers & Pharmaceutical Chemistry to Plant Science & Genetics in Agriculture.  The Center’s teams of highly qualified researchers comprise Heads of Labs and Research Groups comprehensively ranging through Nano-Medicine & Nano Delivery Systems, Tumour Micro-environment, Neurobiology, Pain Relief & Plasticity, Molecular Modeling & Drug Design, Immuno-pharmacology, Free Radicals, Stress and Plant Pathogen Interactions. 

The Hebrew University School of Pharmacy’s Multidisciplinary Center for Cannabinoid Research is integrating, coordinating and conducting this exciting research on cannabinoids, endocannabinoids and medical Cannabis, focusing on the following areas:

  • CANCER
  • PAIN
  • INFLAMATION & STRESS MANAGEMENT
  • IMMUNITY
  • METABOLISM
  • DRUG DELIVERY & NANOTECHNOLOGY
  • PHARMACEUTICAL CHEMISTRY
  • NEUROSCIENCE and PLANT SCIENCE & GENETICS


One of its major objectives is to foster collaborations between its own participating laboratories and many other well-established groups around the globe who are conducting research on cannabinoids, endocannabinoids and medical Cannabis.

Contact Us

Videos

Scientists from the Hebrew University (HU) have pioneered medical marijuana research for over 50 years.

The establishment of the Multidisciplinary Center for Cannabinoid Research (MCCR) at the School of Pharmacy of the Hebrew University in Israel has great relevance at this specific time in modern history – a time when both international academic institutions and mega-pharmaceutical companies all around the globe are channeling enormous efforts towards, and investing heavily in basic and clinical research in this exciting new field. 

The MCCR fills the need for a central, professional body who undertakes to integrate and coordinate all these worldwide research activities into one cohesive whole – assisting collaborations and disseminating collective information.  

The MCCR is staffed by eminent scientists and Medical Doctors from a variety of faculties at the Hebrew University and Hadassah-University Medical Center. The faculties involved span the entire spectrum relevant to this research – from Medicine, Medicinal Chemistry, Biotechnology, Biopolymers & Pharmaceutical Chemistry to Plant Science & Genetics in Agriculture.  The Center’s teams of highly qualified researchers comprise Heads of Labs and Research Groups comprehensively ranging through Nano-Medicine & Nano Delivery Systems, Tumour Micro-environment, Neurobiology, Pain Relief & Plasticity, Molecular Modeling & Drug Design, Immuno-pharmacology, Free Radicals, Stress and Plant Pathogen Interactions. 

DryGair Energies Ltd. is an innovative Ag-Tech company that offers world-leading dehumidification solution for greenhouses, indoor growing facilities and drying rooms. Since its establishment, DryGair has turned an innovative growing concept for treating greenhouse humidity into an internationally recognized agricultural technology company, with presence in major markets in Europe, North America, and the rest of the world.

The concept incorporates the most efficient refrigerant-based dehumidification technology for greenhouses together with patent-protected design for creating air circulation that makes it easy to achieve optimal uniformity of humidity and temperature levels around the plants.

Contact Us

Videos

DryGair is a standalone dedicated dehumidifier designed for maximum efficiency in an agricultural setting

DryGair for Cannabis greenhouse - 360° view

DryGair Energies Ltd. is an innovative Ag-Tech company that offers world-leading dehumidification solution for greenhouses, indoor growing facilities and drying rooms. Since its establishment, DryGair has turned an innovative growing concept for treating greenhouse humidity into an internationally recognized agricultural technology company, with presence in major markets in Europe, North America, and the rest of the world.

The concept incorporates the most efficient refrigerant-based dehumidification technology for greenhouses together with patent-protected design for creating air circulation that makes it easy to achieve optimal uniformity of humidity and temperature levels around the plants.

Contact Us

Videos

DryGair is a standalone dedicated dehumidifier designed for maximum efficiency in an agricultural setting

DryGair for Cannabis greenhouse - 360° view

BioDiligence was established by a group of Israeli biotech professionals with strong academic background. Our mission is to help biotech companies and investors make the best decisions possible while bringing them expertise which is essential to deliver value. Compared to other traditional consulting firms we take the caliber, professionalism and intellectual rigor of Israel’s finest to provide our clients with a turn-key tailored solutions.

Our team consists of highly educated analysts, all with Ph.D.’s and proven experience in biotechnology, agricultural biotechnology, and medical cannabis. Our experience and track record in Venture Capital consultation allows us to view the products we analyze from wider perspectives, such as understanding and analyzing the technology, competitive environment, level of innovation and regulation.

Our work helps to create an environment for investors allowing them to focus their time and resources on evaluating an appropriately researched deal, instead of assessing technology and capabilities.

Contact Us

Our founder Dr. Inbar Maymon-Pomeranchik is a Scientist and Biotech investment consultant Expert, specializing in Life science, Biotech, Ag-tech and a particular expertise in the global medical cannabis industry.

Inbar brings more than 15 years of experience in molecular & genetic research at the academy and as an R&D researcher and project leader in the Biotech industry in large, small and start-up technology corporates.

Due to Inbar’s vast knowledge, you will often see her speaking at global conferences, sharing her knowledge and exposing investors to insights, various opportunities and key industry topics

As an investment consultant, Inbar was responsible for the scientific DD and achieved a major goal by introducing & contributing to the closing of investments in highly promising companies.

BioDiligence was established by a group of Israeli biotech professionals with strong academic background. Our mission is to help biotech companies and investors make the best decisions possible while bringing them expertise which is essential to deliver value. Compared to other traditional consulting firms we take the caliber, professionalism and intellectual rigor of Israel’s finest to provide our clients with a turn-key tailored solutions.

Our team consists of highly educated analysts, all with Ph.D.’s and proven experience in biotechnology, agricultural biotechnology, and medical cannabis. Our experience and track record in Venture Capital consultation allows us to view the products we analyze from wider perspectives, such as understanding and analyzing the technology, competitive environment, level of innovation and regulation.

Our work helps to create an environment for investors allowing them to focus their time and resources on evaluating an appropriately researched deal, instead of assessing technology and capabilities.

Contact Us

Our founder Dr. Inbar Maymon-Pomeranchik is a Scientist and Biotech investment consultant Expert, specializing in Life science, Biotech, Ag-tech and a particular expertise in the global medical cannabis industry.

Inbar brings more than 15 years of experience in molecular & genetic research at the academy and as an R&D researcher and project leader in the Biotech industry in large, small and start-up technology corporates.

Due to Inbar’s vast knowledge, you will often see her speaking at global conferences, sharing her knowledge and exposing investors to insights, various opportunities and key industry topics

As an investment consultant, Inbar was responsible for the scientific DD and achieved a major goal by introducing & contributing to the closing of investments in highly promising companies.

iCANsee is harnessing nanotechnology to pioneer the ocular delivery of cannabinoids.

Nanotechnology is the foundation of an effective delivery platform for ocular medications set to revolutionize eye care.

Human eyes have a high density of cannabinoid receptors making them receptive to cannabis treatments.

Contact Us

Docs

iCANsee Deck

Current ocular treatment options are inefficient, with few patients finding relief. These options include:

• Ocular Steroids
• Artificial Tears
• NSAIDs (Nonsteroidal Anti Inflammatory Drugs)

Our findings for THC suggest that a dual CB1/GPR18 agonist may prove advantageous. The study of phytocannabinoids such as THC and CBD, but also others derived from the plant, may, therefore, point to novel strategies to promote ocular health.

Δ9-Tetrahydrocannabinol, an active ingredient of the plant Cannabis Sativa, is an agonist of the cannabinoid receptors CB1 and CB2 that could potentially be such a dual-acting, antiglaucoma agent. The presence of cannabinoid receptors in the ocular tissues has been recently confirmed, which supports the concept that a localized IOP-reducing mechanism, rather than the central nervous system, is involved.

We subsequently tested the efficacy of our formulation in whole-eye experiments by loading the nanoparticles with cannabigerolic acid (CBGA). Our formulation exhibits over a 300% increase in trans-corneal penetration over control formulations. This work paves the way for the introduction of novel products targeting ocular diseases to the market.

iCANsee is harnessing nanotechnology to pioneer the ocular delivery of cannabinoids.

Nanotechnology is the foundation of an effective delivery platform for ocular medications set to revolutionize eye care.

Human eyes have a high density of cannabinoid receptors making them receptive to cannabis treatments.

Contact Us

Docs

iCANsee Deck

Current ocular treatment options are inefficient, with few patients finding relief. These options include:

• Ocular Steroids
• Artificial Tears
• NSAIDs (Nonsteroidal Anti Inflammatory Drugs)

Our findings for THC suggest that a dual CB1/GPR18 agonist may prove advantageous. The study of phytocannabinoids such as THC and CBD, but also others derived from the plant, may, therefore, point to novel strategies to promote ocular health.

Δ9-Tetrahydrocannabinol, an active ingredient of the plant Cannabis Sativa, is an agonist of the cannabinoid receptors CB1 and CB2 that could potentially be such a dual-acting, antiglaucoma agent. The presence of cannabinoid receptors in the ocular tissues has been recently confirmed, which supports the concept that a localized IOP-reducing mechanism, rather than the central nervous system, is involved.

We subsequently tested the efficacy of our formulation in whole-eye experiments by loading the nanoparticles with cannabigerolic acid (CBGA). Our formulation exhibits over a 300% increase in trans-corneal penetration over control formulations. This work paves the way for the introduction of novel products targeting ocular diseases to the market.

NRGene is a Genomics company that provides turn-key solutions. Relying on a vast proprietary database and AI-based technologies, we provide the largest seed and food companies in the world with the computational tools they need to maximize their crop yield, significantly saving them time and cost. NRGene’s tools have already been implemented by some of the leading agribiotech companies worldwide, as well as the most influential research teams in academia.

Contact Us

Videos

With global food demand constantly on the rise, we must learn to grow more for less. Our turn-key big-data solutions offer breeders the opportunity to maximize their agricultural yield, achieving better results in record time.

Data-driven analytics and machine learning are go-to resources for a wide spectrum of modern industries, from mobility solutions to financial management. Everyone’s looking for the perfect symbiosis of information and output—but what does all that data have to do with corn and cannabis? Welcome to the burgeoning field of agricultural genomics, NRGene’s specialty. As CEO Jonathan Jaglom explains, “NRGene plays in the world of molecular breeding, combining the genetic side of breeding together with the traditional.” In other words, NRGene’s solutions build on thousands of years of agricultural selective breeding and crossbreeding techniques to help its clients maximize their products.

NRGene is a Genomics company that provides turn-key solutions. Relying on a vast proprietary database and AI-based technologies, we provide the largest seed and food companies in the world with the computational tools they need to maximize their crop yield, significantly saving them time and cost. NRGene’s tools have already been implemented by some of the leading agribiotech companies worldwide, as well as the most influential research teams in academia.

Contact Us

Videos

With global food demand constantly on the rise, we must learn to grow more for less. Our turn-key big-data solutions offer breeders the opportunity to maximize their agricultural yield, achieving better results in record time.

Data-driven analytics and machine learning are go-to resources for a wide spectrum of modern industries, from mobility solutions to financial management. Everyone’s looking for the perfect symbiosis of information and output—but what does all that data have to do with corn and cannabis? Welcome to the burgeoning field of agricultural genomics, NRGene’s specialty. As CEO Jonathan Jaglom explains, “NRGene plays in the world of molecular breeding, combining the genetic side of breeding together with the traditional.” In other words, NRGene’s solutions build on thousands of years of agricultural selective breeding and crossbreeding techniques to help its clients maximize their products.

Seach Medical Group, pioneering the field of medical cannabis in Israel and worldwide since 2008. Founded by the Sarid family, 3rd generation of farming experts, who were exposed to the great medical potential of cannabis during their father’s unfortunate sickness. With the growing awareness about cannabis and its medicinal benefits, the Sarid family has spent many years researching and developing medical cannabis products of uncompromising quality with the goal of improving the lives of thousands of patients. The vast knowledge and experience gained over the last decade has allowed the company to continuously improve the quality of its products, while advancing the company’s technological capabilities.

Contact Us

Videos

Shay Avraham Sarid, Co-Founder & CTO of Seach Medical Group in Israel ,discussing the advantages this country has in the field of medical cannabis.

Seach’s wide variety of exclusive genetics, global network of strategic partnerships, groundbreaking clinical trials, and development of novel cannabis technology, gives Seach a leading presence in the global cannabis industry.

Today, and for the last decade, the company has been supplying high-quality medical cannabis products to leading pharmaceutical brands, as well as thousands of patients and pharmacies on a monthly basis. All the company’s products are cultivated and manufactured in accordance with the most stringent standards and instructions of the Ministry of Health.

Seach Medical Group, pioneering the field of medical cannabis in Israel and worldwide since 2008. Founded by the Sarid family, 3rd generation of farming experts, who were exposed to the great medical potential of cannabis during their father’s unfortunate sickness. With the growing awareness about cannabis and its medicinal benefits, the Sarid family has spent many years researching and developing medical cannabis products of uncompromising quality with the goal of improving the lives of thousands of patients. The vast knowledge and experience gained over the last decade has allowed the company to continuously improve the quality of its products, while advancing the company’s technological capabilities.

Contact Us

Videos

Shay Avraham Sarid, Co-Founder & CTO of Seach Medical Group in Israel ,discussing the advantages this country has in the field of medical cannabis.

Seach’s wide variety of exclusive genetics, global network of strategic partnerships, groundbreaking clinical trials, and development of novel cannabis technology, gives Seach a leading presence in the global cannabis industry.

Today, and for the last decade, the company has been supplying high-quality medical cannabis products to leading pharmaceutical brands, as well as thousands of patients and pharmacies on a monthly basis. All the company’s products are cultivated and manufactured in accordance with the most stringent standards and instructions of the Ministry of Health.

events

About

©2019 All rights reserved | Terms of use & Privacy Policy

Close Menu
Share This
×
×

Cart